Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PFE

Pfizer Inc

May 05 • 04:00PM ET

26.45

+0.15 0.57 %

Healthcare • Drug Manufacturers - General • USA • Large • NYSE

May 05, 2:21 PMPfizer beats Q1 estimates, reaffirms 2026 guidance, targets high-single-digit annual revenue growth from 2029

Peers: BMY MRK SNY AMGN ABBV NVS JNJ GSK LLY AZN-D

| Held by: VTI VOO IVV SPY VTV XLV VYM DVY VHT FDL

Scroll to Statements

Index	S&P 500	P/E	19.52	EPS (ttm)	1.36	Insider Own	0.07%	Shs Outstand	5.70B	Perf Week	-0.11%
Market Cap	150.46B	Forward P/E	9.33	EPS next Y	2.83	Insider Trans	0.00%	Shs Float	5.68B	Perf Month	-4.96%
Enterprise Value	202.14B	PEG	-	EPS next Q	0.68	Inst Own	67.14%	Short Float	2.35%	Perf Quarter	2.64%
Income	7.75B	P/S	2.38	EPS this Y	-8.06%	Inst Trans	0.11%	Short Ratio	3.45	Perf Half Y	7.30%
Sales	63.31B	P/B	1.67	EPS next Y	-4.27%	ROA	3.67%	Short Interest	133.41M	Perf YTD	6.22%
Book/sh	15.81	P/C	11.51	EPS next 5Y	-8.80%	ROE	8.87%	52W High	28.75 -7.98%	Perf Year	10.81%
Cash/sh	2.30	P/FCF	16.58	EPS past 3/5Y	-37.19% -3.57%	ROIC	5.14%	52W Low	21.97 20.39%	Perf 3Y	-31.28%
Dividend Est.	1.75 (6.63%)	EV/EBITDA	8.38	Sales past 3/5Y	-14.56% 8.48%	Gross Margin	65.16%	Volatility	1.84% 2.06%	Perf 5Y	-33.83%
Dividend TTM	1.72 (6.50%)	EV/Sales	3.19	EPS Y/Y TTM	-3.74%	Oper. Margin	27.08%	ATR (14)	0.58	Perf 10Y	-16.86%
Dividend Ex-Date	May 08, 2026	Quick Ratio	0.87	Sales Y/Y TTM	1.36%	Profit Margin	12.23%	RSI (14)	43.51	Recom	2.50
Dividend Gr. 3/5Y	2.23% 2.37%	Current Ratio	1.16	EPS Q/Q	-9.78%	SMA20	-1.79%	Beta	0.31	Target Price	29.02
Payout	126.85%	Debt/Eq	0.72	Sales Q/Q	5.37%	SMA50	-2.43%	Rel Volume	1.44	Prev Close	26.30
Employees	75000	LT Debt/Eq	0.67	Earnings	May 05 BMO	SMA200	2.90%	Avg Volume	38.68M	Price	26.45
IPO	Jan 17, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.92% 4.41%	Trades		Volume	57,656,104	Change	0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-02-26	Upgrade	Argus	Hold → Buy	$35
Feb-25-26	Initiated	RBC Capital Mkts	Underperform	$25
Feb-20-26	Initiated	Barclays	Underweight	$25
Feb-12-26	Downgrade	Daiwa Securities	Outperform → Neutral	$27
Jan-07-26	Resumed	UBS	Neutral	$25
Dec-02-25	Resumed	Citigroup	Neutral	$26
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$30
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$24
Dec-10-24	Resumed	BofA Securities	Neutral	$29
Nov-15-24	Initiated	Wolfe Research	Underperform	$25
Oct-25-24	Resumed	Citigroup	Neutral	$30
Oct-17-24	Initiated	Bernstein	Mkt Perform	$32
Aug-07-24	Upgrade	Daiwa Securities	Neutral → Outperform
Mar-22-24	Downgrade	Argus	Buy → Hold
Feb-23-24	Initiated	Guggenheim	Buy	$36
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$32
Oct-20-23	Resumed	UBS	Neutral	$36 → $34
Oct-16-23	Upgrade	Jefferies	Hold → Buy	$38 → $39
Jul-17-23	Reiterated	JP Morgan	Neutral	$45 → $41
Jul-14-23	Initiated	HSBC Securities	Buy	$50

Show Previous Ratings

May-05-26 04:54PM	Pfizer Inc. Q1 2026 Earnings Call Summary (Moby)
03:56PM	Pfizer CEO Says Digging Out of Post-Covid Hole Will Take a Few More Years (The Wall Street Journal)
02:41PM	Pfizer Beats Sales Estimates As $17 Billion Patent Cliff Looms (GuruFocus.com)
01:30PM	Pfizer pins post 2028 return to growth on new obesity and cancer drugs (Reuters)
12:41PM	Pfizer beats Q1 revenue and profit estimates, reaffirms 2026 guidance (Proactive)
12:30PM	Loading…
12:30PM	Chicken or the Egg? Why We Need to Rethink Data and Funding in Startups (Entrepreneur)
11:05AM	Pfizer tops Q1 expectations on growth from newer products (InvestorsHub)
10:44AM	2 Trendlines in Focus For Pfizer Stock After Earnings (Schaeffer's Research)
09:54AM	BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. (Barrons.com)
09:02AM	Stock Futures Higher on Cooling Oil, Upbeat Earnings (Schaeffer's Research)
08:53AM	Why Pfizer's 'Mild' First-Quarter Report Likely Won't Satisfy Skeptics (Investor's Business Daily)
08:45AM	Pfizer Q1 2026 earnings beat estimates on newer drug growth (Quartz)
08:35AM	Pfizer Posts Better-Than-Expected Revenue, Profit (The Wall Street Journal)
08:00AM	How Pfizers CEO says he uses AI to make decisions (CNN Business)
07:34AM	Pfizer beats first quarter estimates on strong product growth (Investing.com)
07:23AM	Loading…
07:23AM	Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending (The Wall Street Journal)
07:06AM	Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates (Barrons.com)
06:54AM	Pfizer: Q1 Earnings Snapshot (Associated Press)
06:45AM	Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance (Business Wire)
04:59AM	AMD headlines Tuesday's earnings slate (MarketWatch)
May-04-26 07:55PM	Review & Preview: War Redux (Barrons.com)
07:00PM	AMD and Pfizer earnings, job openings, Fedspeak: What to Watch (Yahoo Finance Video)
05:06AM	Protein degraders gain speed as Arvinas scores landmark approval (Pharma Voice)
May-01-26 10:50AM	Eli Lilly Stocks Path To 30% Upside (Trefis)
07:30AM	Eli Lilly: The Most Expensive Stock in Pharma; and Maybe the Best (GuruFocus.com)
Apr-30-26 01:00PM	The Week Ahead: Employment Data, Fed Speeches (Schaeffer's Research)
12:08PM	Thinning revenues: inside the $14bn Eliquis patent cliff (Pharmaceutical Technology)
11:41AM	Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales (Reuters)
Apr-29-26 12:59PM	Pfizer protects $6.4bn heart disease blockbuster from generics, for now (Pharmaceutical Technology)
07:21AM	FDA tests out real-time clinical trials; AbbVie closes in on a KRAS biotech (BioPharma Dive)
06:45AM	Loading…
06:45AM	Pfizers ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma (Business Wire)
03:09AM	OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ... (GuruFocus.com)
02:58AM	AWS CEO Matt Garman sees huge business opportunity for Amazon in AI-powered software: Everything is going to be remade (Fortune)
Apr-28-26 10:17AM	Pfizer Reaches Three Settlement Agreements for VYNDAMAX (Business Wire)
08:28AM	Pfizer deals extend patent life for a top-selling rare disease drug (BioPharma Dive)
Apr-24-26 04:55PM	CureVac sues Moderna for patent infringement over COVID-19 vaccines (Reuters)
01:34PM	Bristol Myers, Pfizer Bring Eliquis to Cost Plus at $345 Monthly (GuruFocus.com)
11:00AM	Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims (Yahoo Finance Video)
06:59AM	Bristol Myers Squibb and Pfizer to Make Eliquis (apixaban) Available via Mark Cuban Cost Plus Drug Company (Business Wire)
Apr-23-26 05:49PM	Regeneron Shares Up on Trump Drug Pricing Deal (Barrons.com)
02:27AM	Richest countries in 2026: New measure of wealth pushes France and Germany out of top ten (Euronews)
Apr-22-26 04:45PM	Pfizer Declares Second-Quarter 2026 Dividend (Business Wire)
11:01AM	Pfizer CFO Dave Denton on Oncology, Obesity, and Pfizers Next Growth Cycle (NYSE)
Apr-21-26 12:23PM	Eli Lilly eyes Kelonia Therapeutics in $7B deal with $3.25B to be paid up front. How to invest early to grow your wealth (Moneywise)
11:51AM	Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026 (Business Wire)
06:29AM	Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy (Pharmaceutical Business Review)
Apr-20-26 10:47AM	Novo's Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%. (Barrons.com)
06:45AM	U.S. FDA Grants Priority Review to sBLA for PADCEV + Keytruda as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility (PR Newswire)
Apr-17-26 04:13PM	Why Is Abbott Stock Trending Lower? (Trefis)
Apr-13-26 11:43AM	How Eli Lilly Stock Rises To $2,000 (Trefis)
Apr-11-26 08:01PM	How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results (Quartz)
Apr-10-26 08:11PM	Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing (Quartz)
Apr-09-26 10:00AM	Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders (Business Wire)
Apr-08-26 12:44PM	Gilead Agrees $5 Billion Tubulis Acquisition To Expand Cancer Drug Pipeline (GuruFocus.com)
Apr-07-26 05:47PM	The $190 Billion 'Diabesity' Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts. (Barrons.com)
Apr-02-26 04:05PM	Trump slaps steep tariffs on patented drug imports (Supply Chain Dive)
11:37AM	Boost Pfizer's Already Hefty 6% Dividend Yield With A Covered Call (Investor's Business Daily)
08:01AM	JNJ Stocks 60% Breakout: Why Wall Street is Torn (Trefis)
Apr-01-26 04:07PM	Why 2026 Is Biotech's Comeback Year (Barrons.com)
04:05PM	Oric Shares Fall 40% as Cancer-Drug Data Falls Short of Expectations (The Wall Street Journal)
10:02AM	Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer - And Plunges (Investor's Business Daily)
09:30AM	Pfizer Pulls Back From South San Francisco (GuruFocus.com)
04:00AM	Will Pfizers Lyme disease gamble pay off or set the space back? (Pharma Voice)
Mar-31-26 03:45PM	$2 Billion Bayer Verdict: What the Roundup Decision Means for MAHA (Exec Edge)
Mar-30-26 10:44AM	Pharma Stocks Pfizer, GSK Offer Defensive Plays in an Uncertain Market: Charts (Barrons.com)
09:37AM	Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. What It Means for the Stock. (Barrons.com)
09:17AM	Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises. (Barrons.com)
02:03AM	Connecting Excellence Group appoints chief performance and growth officer (Proactive)
Mar-27-26 11:40AM	Consecutive approvals of Opdivo for Hodgkins lymphoma to boost sales growth (Clinical Trials Arena)
Mar-26-26 01:30AM	22 S&P 500 Stocks Yield More Than 5%. 6 That Are Worth Buying. (Barrons.com)
Mar-24-26 11:02AM	Pfizer CFO Dave Denton Highlights Firms Recent Oncology Milestones (NYSE)
10:39AM	Pfizer Reports 73% Lyme Vaccine Efficacy as Trial Results Complicate Outlook (GuruFocus.com)
10:00AM	Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts (Business Wire)
05:57AM	Immutrin raises $87M to advance drug for progressive heart disease (BioPharma Dive)
Mar-23-26 02:31PM	Pfizer-Valneva Lyme disease vaccine falls short as low cases skew results (Clinical Trials Arena)
01:00PM	Stocks Rise, Oil Falls as Trump Eases Iran Threats: Markets Wrap (Bloomberg)
12:46PM	Pfizer's Lyme Vaccine Shows Strong Efficacy, but Misses Mark in Study (The Wall Street Journal)
09:54AM	Mixed results for Lyme disease vaccine hit Valneva shares (AFP)
08:06AM	Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results (BioPharma Dive)
08:00AM	Telescope Innovations Announces Expansion of Consulting Role for Dr. Joel M. Hawkins, Industry Leader in Process Chemistry Automation (TMX Newsfile)
07:07AM	Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial (MarketWatch)
07:02AM	Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial (The Wall Street Journal)
06:45AM	Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial (Business Wire)
Mar-22-26 09:00PM	IP Group PLC (IPZYF) Full Year 2025 Earnings Call Highlights: Strong NAV Growth Amid Market ... (GuruFocus.com)
Mar-20-26 04:30PM	Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC (Business Wire)
Mar-19-26 09:47AM	ImmuPharma, Ilika, Coinsilium Group, IP Group, Team Internet Group - Small Cap Week in Review (Proactive)
07:37AM	Pfizer aims for wider use of PARP drug in prostate cancer with new data (BioPharma Dive)
07:30AM	The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients (Fortune)
06:45AM	TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer (Business Wire)
Mar-18-26 05:00PM	Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
02:29PM	Analysis-TrumpRx lists many medicines at prices higher than paid in UK (Reuters)
Mar-17-26 03:01PM	Pfizer Reports Positive Mid-Stage Breast Cancer Trial Results (GuruFocus.com)
07:56AM	Bicycle to lay off 30% of staff, pivot away from Padcev challenger (BioPharma Dive)
07:15AM	Pfizers Ibrance successor moves forward with new study data (BioPharma Dive)
06:45AM	Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer (Business Wire)
05:53AM	Empire Metals, Atlantic Lithium, ImmuPharma, IP Group, Light Science Technologies, ATOME (Proactive)
Mar-16-26 11:38AM	IP Group CEO on 2025 highlights, NAV uplift, Pfizer royalties & capital allocation (Proactive)
Mar-15-26 05:05PM	Man's dog was riddled with tumors and dying. He used ChatGPT to design a custom cancer vaccine, stunning researchers (Moneywise)
Mar-13-26 11:38PM	Ecuador trade deal: Trump administration targets lower food and tech levies (Investing.com)
07:54AM	GSKs RSV vaccine wins broader FDA clearance (BioPharma Dive)

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SAHNI PAYAL	Executive Vice President	Feb 25 '26	Option Exercise	33.82	56,888	1,923,952	82,816	Feb 27 06:35 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 25 '26	Option Exercise	33.82	122,907	4,156,715	282,186	Feb 27 06:35 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 25 '26	Option Exercise	33.82	17,558	593,812	29,744	Feb 27 06:35 PM
BOURLA ALBERT	Chairman & CEO	Feb 25 '26	Option Exercise	33.82	491,626	16,626,791	864,215	Feb 27 06:34 PM
Fonseca Lidia	Executive Vice President	Feb 25 '26	Option Exercise	33.82	56,888	1,923,952	101,579	Feb 27 06:34 PM
McDermott Michael	Executive Vice President	Feb 25 '26	Option Exercise	33.82	37,925	1,282,624	114,534	Feb 27 06:34 PM
Dolsten Mikael	Former Officer	May 23 '25	Proposed Sale	23.09	59,781	1,380,632		May 23 10:54 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PFE

Pfizer Inc

Upgrade your Finviz experience